Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis
Ticagrelor exerts anti-RCC effects <i>via</i> blockade of the EGFR/PI3K/AKT signaling axis, highlighting its translational potential and positioning this pathway as a therapeutic target and possible biomarker in RCC.
Authors
- Lin Zhang (ORCID: https://orcid.org/0000-0002-4360-5523)
- Haihong Fang (ORCID: https://orcid.org/0000-0001-9466-6062)
- Yuanqiao He
- Ting Zhou
- Tongqi Liu
- Yuxiu Yang
- Yongmei Guo
Institutions
- Nanchang University (CN)
- Jiangxi Science and Technology Normal University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Kai Biotech (South Korea) (KR)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1080/07853890.2026.2635268
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00